Canaccord Genuity Reiterates a 'Buy' on Tranzyme (TZYM); POI Doctor Call Key Takeaways: Entereg Notably Shortens Stay
Tweet
Share
E-mailGet Alerts TZYM Hot Sheet
Price: $0.48 --0%
Rating Summary:
3 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
3 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Tranzyme (NASDAQ: TZYM) price target of $7.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on lead drug ulimorelin (uli) potential for Phase 3 clinical, commercial success in postoperative ileus (POI). POI is a post-surgical gut disorder that leads to longer hospital stays and higher healthcare costs. We believe the two uli Phase 3 POI trials will yield positive data in H1/12, an NDA submission in early 2013 and a 2014 launch. Our $7 target is based on a pNPV analysis and includes potential sales of Phase 2 TZP-102 for diabetic gastroparesis."
"Dr. Binderow thinks Entereg provides meaningful benefit in both open and laparoscopic GI surgery, supported by Premier study data...Dr. Binderow views uli as potentially achieving wider use than Entereg due to a cleaner safety profile and independence of prior opioid use."
For an analyst ratings summary and ratings history on Tranzyme click here. For more ratings news on Tranzyme click here.
Shares of Tranzyme closed at $5.10 yesterday.
Analyst, Ritu Baral, said, "Reiterate rating and price target on lead drug ulimorelin (uli) potential for Phase 3 clinical, commercial success in postoperative ileus (POI). POI is a post-surgical gut disorder that leads to longer hospital stays and higher healthcare costs. We believe the two uli Phase 3 POI trials will yield positive data in H1/12, an NDA submission in early 2013 and a 2014 launch. Our $7 target is based on a pNPV analysis and includes potential sales of Phase 2 TZP-102 for diabetic gastroparesis."
"Dr. Binderow thinks Entereg provides meaningful benefit in both open and laparoscopic GI surgery, supported by Premier study data...Dr. Binderow views uli as potentially achieving wider use than Entereg due to a cleaner safety profile and independence of prior opioid use."
For an analyst ratings summary and ratings history on Tranzyme click here. For more ratings news on Tranzyme click here.
Shares of Tranzyme closed at $5.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
- Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
